Dermatology specialist appoints chairman

George Horner joins Creabilis of Luxembourg

Creabilis, a Luxembourg-based clinical stage biotechnology company focused on dermatological diseases, has appointed George Horner as chairman.

Horner has more than 40 years of industry experience gained with biotech and big pharma companies. He was most recently ceo of Prestwick Pharmaceuticals, a private CNS company that was sold to Biovail Corporation and Ovation Pharmaceuticals in 2008.

Prior to joining Prestwick, Horner was ceo of Vicuron, a publicly listed anti-infectives company that was sold to Pfizer for US$1.9bn in 2005. He also worked for Ligand Pharmaceuticals following a career at Abbott Laboratories where rose to president of the company’s business in Canada.

‘I have been attracted to this opportunity by the company’s rich pipeline of clinical and pre-clinical drug candidates focused on dermatological indications, its deep understanding of the science behind a number of serious skin disorders, as well as its technology platform with broad utility. I am sure that from this strong base we will be able to generate significant value for Creabilis shareholders,’ said Horner.

You may also like

Finance

Creabilis establishes UK operation

Location in Kent broadens the county’s links with the pharma industry
Manufacturing

Lonza appoints Hans Trees as Global Head of Communications

Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Ingredients

Safe and accurate flow measurement for pharmaceutical production

Oval Gear (OG) meters from Titan Enterprises, fitted with a Namur sensor, provide consistent, accurate measurement across a wide range of liquids, from low-viscosity solvents to more viscous pharmaceutical ingredients
Research & Development

The IND advantage: why early derisking is a strategic imperative for complex biologics

As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Pharmaceutical

CellCarta and Leica Biosystems expand companion disgnostic development model partnership

Building on a successful CDx joint development model in China, the pair will aim to bring the end-to-end development framework to global customers to help their customers streamline the path to global CDx commercialisation
Manufacturing

ystral opens ATEX-compliant trial centre in Germany to expand customer process development capacity

The new facility, based in Ballrechten-Dottingen, will be able to handle flammable and explosive media testing across pharma, coatings and food applications, with remote livestream access and in-house particle size and viscosity analysis
Pharmaceutical

CelLBxHealth and AstraZeneca sign Master Services Agreement

The new contract establishes CelLBxHealth as a qualified service provider to AstraZeneca, allowing it to support drug discovery and development through CTC-powered analytics of clinical trial samples with its Parsortix platform
Subscribe now